Oncternal Therapeutics Equity 2024

Oncternal Therapeutics Aktienanalyse

What does Oncternal Therapeutics do?

Oncternal Therapeutics Inc is an American biotechnology company specializing in the development of cancer drugs. The company was founded in 2013 and is headquartered in San Diego, California. Oncternal Therapeutics' business model is based on identifying promising cancer drugs and advancing them through the approval process of regulatory authorities. The company utilizes both public and private funds to finance its research projects. As part of this, Oncternal Therapeutics participates in clinical trials and actively collaborates with experts in the clinical field. Over the years, the company has established several divisions to make its work more effective and efficient. One of these divisions focuses on developing molecules that activate the body's immune system against cancer cells. A prime example of this is the drug Cirmtuzumab. This antibody blocks signals that promote the growth of cancer cells while simultaneously activating the immune system to target tumor cells. Cirmtuzumab has shown positive results in the treatment of chronic lymphocytic leukemia, a form of blood cancer. Another division of Oncternal Therapeutics focuses on developing drugs that target cancer stem cells. These cells are responsible for the growth and spread of cancer cells in the body. Medications like the ROR1-targeting CAR-T preparation directly target these types of cancer cells and are intended to make cancer drugs more effective and targeted. Oncternal Therapeutics stands out from other cancer researchers in its ability to treat multiple myelomas, a cancer of the bone marrow cells, more effectively. The company has developed specific drugs that can influence the expression of specific genes in myeloma cells, thereby halting tumor growth. Key myeloma products from Oncternal Therapeutics include the TK216 and OT-82 preparations. In summary, Oncternal Therapeutics Inc is an innovative biotechnology company specializing in the development of cancer drugs. The company has a wide range of divisions, from developing drugs that activate the immune system against cancer cells to targeting cancer stem cells. The company's products show promising results in the treatment of various types of cancer and have the potential to bring about positive change for thousands of cancer patients worldwide. Oncternal Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Oncternal Therapeutics's Equity

Oncternal Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Oncternal Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Oncternal Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Oncternal Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Oncternal Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Oncternal Therapeutics Stock

What is the equity of Oncternal Therapeutics this year?

Oncternal Therapeutics has equity of 30.05 M USD this year.

What was the equity of Oncternal Therapeutics compared to the previous year?

The equity of Oncternal Therapeutics has increased/decreased by -50.71% decreased compared to the previous year.

What impact does a high equity have on investors of Oncternal Therapeutics?

A high equity is advantageous for investors of Oncternal Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Oncternal Therapeutics?

A low equity can be a risk for investors of Oncternal Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Oncternal Therapeutics affect the company?

An increase in equity of Oncternal Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Oncternal Therapeutics affect the company?

A reduction in equity of Oncternal Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Oncternal Therapeutics?

Some factors that can affect the equity of Oncternal Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Oncternal Therapeutics so important for investors?

The equity of Oncternal Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Oncternal Therapeutics take to change the equity?

To change equity, Oncternal Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Oncternal Therapeutics pay?

Over the past 12 months, Oncternal Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncternal Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Oncternal Therapeutics?

The current dividend yield of Oncternal Therapeutics is .

When does Oncternal Therapeutics pay dividends?

Oncternal Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncternal Therapeutics?

Oncternal Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Oncternal Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncternal Therapeutics located?

Oncternal Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncternal Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncternal Therapeutics from 6/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/2/2024.

When did Oncternal Therapeutics pay the last dividend?

The last dividend was paid out on 6/2/2024.

What was the dividend of Oncternal Therapeutics in the year 2023?

In the year 2023, Oncternal Therapeutics distributed 0 USD as dividends.

In which currency does Oncternal Therapeutics pay out the dividend?

The dividends of Oncternal Therapeutics are distributed in USD.